Company announcement 19_ 2023 Orphazyme will consolidate it share in a ratio of 1000_1
Nov 2, 2023
Company-announcement-19_-2023-Orphazyme-will-consolidate-it-share-in-a-ratio-of-1000_1. pdf
Read moreCompany-announcement-18-2023-decisions-of-extraordinary-general-meeting
Nov 2, 2023
Company-announcement-18-2023-decisions-of-extraordinary-general-meeting. pdf
Read moreNotice to convence an extraordinary general meeting
Oct 11, 2023
Uploads/Company-announcement-17_2023-Notice-to-convence-an-extraordinary-general-meeting. pdf
Read moreIntention of reverse stock split
Oct 11, 2023
Uploads/Company-announcement-16_2023-Announcement-about-intention-of-reverse-stock-split. pdf
Read moreRestricted stock units_to board and management
Oct 6, 2023
Company-announcement-15_2023-Restricted-stock-units_to-board-and-management. pdf
Read morePreliminary court approval on US Security class action case
Oct 6, 2023
Company-announcement-14_2023-Preliminary-court-approval-on-US-Security-class-action-case. pdf
Read moreNew CEO appointed
Sep 20, 2023
Company-announcement-13_23-Orphazyme-appoints-Jakob-Bendtsen-as-new-CEO. pdf
Read moreCompany announcement 12/2023 Interim Report First Half 2023
Sep 12, 2023
Company announcement 12/2023 Interim Report First Half 2023
Read moreChange in management
May 30, 2023
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company.
Read moreMajor shareholder announcement
May 19, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S, that as of May 16, 2023, Scandinavian Investment Group A/S holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read more